Drug intelligence / Profile preview

Dengue Fever Genetic Vaccine (Asia Biotech)

Development stage: Preclinical
Lead developer: Asia Biotech
Modality: Vaccines & Immunotherapeutics

Overview

The Dengue Fever Genetic Vaccine is an adenoviral vector-based vaccine candidate developed by Asia Biotech for the prevention of Dengue fever. Utilizing a genetic vaccine platform, the candidate is designed to deliver genetic sequences of the dengue virus into host cells to stimulate a robust and protective immune response. As of the latest reports, the vaccine is in the preclinical stage of development, with initial studies conducted at Russian scientific institutes followed by primate testing in Malaysia.

Other names: Dengue Fever Vaccine (Genetic Vaccine)adenoviral vector vaccinegenetic vaccine

Beyond the preview

Go deeper on Dengue Fever Genetic Vaccine (Asia Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dengue Fever Genetic Vaccine (Asia Biotech).

Explore the full profile